Skip to main content
SpringerLink
Log in

Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung

Akutmanagement und Sekundärprävention des Schlaganfalls, Teil II

Policy document of the Austrian Society of Stroke Research

Acute management and secondary prevention of stroke, Part II

  • Leitlinien
  • Published:
Gefässchirurgie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hacke W, Donnan G, Fieschi C et al. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768–774

    Article  PubMed  Google Scholar 

  2. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (2000) Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31: 2912–2919

    Google Scholar 

  3. Hill M, Buchan A for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators (2005) Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172: 1307–1312

    PubMed  Google Scholar 

  4. Graham G (2003) Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 34: 2847–2850

    Article  PubMed  CAS  Google Scholar 

  5. Wahlgren N, Ahmed N, Dávalos A et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369: 275–282

    Article  PubMed  CAS  Google Scholar 

  6. Adams HP, Del Zoppo G, Alberts MJ et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655–1711

    Article  PubMed  Google Scholar 

  7. Kohrmann MJ, Juttler E, Fiebach J et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5: 661–667

    Article  PubMed  Google Scholar 

  8. Külkens S, Ringleb P, Hacke W (2004) Empfehlungen der European Stroke Initiative (EUSI) zur Behandlung des ischämischen Schlaganfalls – Aktualisierung 2003. Nervenarzt 75: 368–379

    Article  PubMed  Google Scholar 

  9. Zangerle A, Kiechl S, Spiegel M et al. (2007) Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 68: 39–44

    Article  PubMed  CAS  Google Scholar 

  10. Del Zoppo G, Higashida R, Furlan A et al. (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29: 4–11

    Google Scholar 

  11. Alexandrov A, Molina C, Grotta J et al. CLOTBUST Investigators (2004) Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351: 2170–2178

    Article  PubMed  CAS  Google Scholar 

  12. Daffertshofer M, Gass A, Ringleb P et al. (2005) Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 36: 1441–1446

    Article  PubMed  Google Scholar 

  13. Smith W (2006) Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 27: 1177–1182

    PubMed  CAS  Google Scholar 

  14. Gralla J, Schroth G, Remonda L et al. (2006) Mechanical thrombectomy for acute ischemic stroke: thrombus-device interaction, efficiency, and complications in vivo. Stroke 37: 3019–3024

    Article  PubMed  Google Scholar 

  15. Lees K, Zivin J, Ashwood TD et al. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588–600

    Article  PubMed  CAS  Google Scholar 

  16. Antithrombotic Trialists‘ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86

    Article  Google Scholar 

  17. Algra A, Van Gijn J, Algra A, Koudstaal PJ (1999) Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 66: 557–559

    Article  PubMed  CAS  Google Scholar 

  18. Antithrombotic Trialists‘ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists‘ Collaboration. BMJ 308: 81–106

    Google Scholar 

  19. Sacco RL, Adams R, Albers G et al. American Heart Association, American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention, American Academy of Neurology (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37: 577-617

    Article  PubMed  Google Scholar 

  20. Leys D, Kwiecinski H, Bogousslavsky J et al. (2004) Prevention. Cerebrovasc Dis 17: 15–29

    Article  PubMed  Google Scholar 

  21. Solomon SD, Pfeffer MA, McMurray JJ et al. for the APC and PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028–1035

    Article  PubMed  CAS  Google Scholar 

  22. Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308

    Article  PubMed  CAS  Google Scholar 

  23. Frelinger AL III, Furman MI, Linden MD et al. (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113: 2888–2896

    Article  PubMed  CAS  Google Scholar 

  24. Chan FK, Ching JY, Hung LC et al. (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

    Article  PubMed  CAS  Google Scholar 

  25. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349: 1569–1581

    Article  Google Scholar 

  26. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349: 1641–1649

    Article  Google Scholar 

  27. Diener HC, Cunha L, Forbes C et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13

    Article  PubMed  CAS  Google Scholar 

  28. ESPRIT Study Group; Halkes PH, Gijn J van et al. (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673

    Article  CAS  Google Scholar 

  29. CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  Google Scholar 

  30. Bennett CL, Connors JM, Carwile JM et al. (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342: 1773–1777

    Article  PubMed  CAS  Google Scholar 

  31. Diener HC, Bogousslavsky J, Brass LM et al. on behalf of the MATCH investigators (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  PubMed  CAS  Google Scholar 

  32. Bhatt DL, Fox KA, Hacke W et al. for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  PubMed  CAS  Google Scholar 

  33. Batt DL, Flather MD, Hacke W et al. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49: 1982–1988

    Article  Google Scholar 

  34. Kasner SE, Lynn MJ, Chimowitz MI et al.; Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators (2006) Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology 67: 1275–1278

    Article  PubMed  CAS  Google Scholar 

  35. Berkefeld J, Hamann GF, Mesnil R du et al. (2006) Endovascular treatment for intracranial stenoses: a common statement by neurologists and neuroradiologists. Nervenarzt 77: 1444–1455

    Article  PubMed  CAS  Google Scholar 

  36. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J, HArt R et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912

    Article  CAS  Google Scholar 

  37. Bates SM, Greer IA, Hirsh J, Ginsberg JS (2004) Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 26: 627S–644S

    Article  Google Scholar 

  38. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342: 1255–1262

    Google Scholar 

  39. Halperin JL for the Executive Steering Committee, SPORTIF III, and V Study Investigators (2003) Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146: 431–438

    Article  PubMed  CAS  Google Scholar 

  40. Braunwald E, Antman EM, Beasley JW et al. for the American College of Cardiology, American Heart Association, Committee on the Management of Patients With Unstable Angina (2002) Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40: 1366–1374

    Article  PubMed  Google Scholar 

  41. Bonow RO, Carabello B, De Leon AC Jr et al. (1998) ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 32: 1486–1588

    Article  Google Scholar 

  42. Rodgers A, MacMahon S, Gamble G et al. (1996) Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ 313: 147

    PubMed  CAS  Google Scholar 

  43. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153

    Article  Google Scholar 

  44. Lawes CMM, Bennett DA, Feigin VL, Rodgers A (2004) Blood pressure and stroke – an overview of published reviews. Stroke 35: 1024–1033

    Article  PubMed  Google Scholar 

  45. Adams HP, Adams RJ, Brott T et al. (2003) Guidelines for the early management of patients with ischemic stroke – a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34: 1056–1083

    Article  PubMed  Google Scholar 

  46. Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists‘ Collaboration. Lancet 362: 1527–1535

    Article  PubMed  CAS  Google Scholar 

  47. Gueyffler F, Bulpitt C, Boissel JP et al. (1999) Antihypertensive drugs in very old people. A subgroup meta-analysis of randomised controlled trials. Lancet 353: 793–796

    Article  Google Scholar 

  48. Rashid P, Leonardi-Bee J, Bath P (2003) Blood pressure reduction and secondary prevention of stroke and other vascular events – a systematic review. Stroke 34: 2741–2748

    Article  PubMed  Google Scholar 

  49. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041

    Article  Google Scholar 

  50. Chobanian AV, Bakris GL, Black HR et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure – The JNC 7 Report. JAMA 289: 2560–2572

    Article  PubMed  CAS  Google Scholar 

  51. Schrader J, Luders S, Kulschewski A et al. (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention – principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1224

    Article  PubMed  CAS  Google Scholar 

  52. Wahlgren NG, MacMahon DG, de Keyser J et al. (1994) The Intravenous Nimodipine West European Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 4: 204–210

    Article  Google Scholar 

  53. Schrader J, Luders S, Kulschewski A et al. (2003) The ACCESS study-evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703

    Article  PubMed  Google Scholar 

  54. Goldstein LB, Adams R, Alberts MJ et al. (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37: 1583–1633

    PubMed  Google Scholar 

  55. Cholesterol Treatment Trialists‘ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366: 1567–1578

    Google Scholar 

  56. Amarenco P, Labreuche J, Lavallée P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909

    Article  PubMed  CAS  Google Scholar 

  57. Grundy SM, Cleeman JI, Merz CN et al. (2004) Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732

    Article  PubMed  Google Scholar 

  58. Amarenco P, Bogousslavsky J, Callahan A et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med 355: 549–559

    Article  PubMed  CAS  Google Scholar 

  59. Berge KG, Canner PL (1991) Coronary drug project: experience with niacin. Eur J Clin Pharmacol (Suppl 1) 40: 49–51

    Article  Google Scholar 

  60. Brown BG, Zhao X-Q, Alan Chait A et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592

    Article  PubMed  CAS  Google Scholar 

  61. Taylor AJ, Sullenberger LE, Lee HJ et al. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517

    Article  PubMed  CAS  Google Scholar 

  62. Rubins HB, Robins SJ, Collins D et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418

    Article  PubMed  CAS  Google Scholar 

  63. Ballantyne CM, Lipka LJ, Sager PT et al. (2004) Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 58: 653–658

    Article  PubMed  CAS  Google Scholar 

  64. Brousseau ME, Schäfer EJ, Wolfe ML (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505–1515

    Article  PubMed  CAS  Google Scholar 

  65. Tanne JH (2006) Pfizer stops clinical trials of heart drug. BMJ 333: 1237

    Article  PubMed  Google Scholar 

  66. Steffen LM, Jacobs DR, Stevens J et al. (2003) Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Clin Nutr 78: 383–390

    PubMed  CAS  Google Scholar 

  67. Joshipura KJ, Ascherio A, Manson JE et al. (1999) Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 282: 1233–1239

    Article  PubMed  CAS  Google Scholar 

  68. Sacks FM, Svetkey LP, Vollmer WM et al. (2001) Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344: 3–10

    Article  PubMed  CAS  Google Scholar 

  69. Alberti KG, Zimmet PZ (1998) Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553

    Article  PubMed  CAS  Google Scholar 

  70. Cleeman JI, Grundy SM, Becker D et al. (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497

    Article  Google Scholar 

  71. Alberti KGMM, Zimmet P, Shaw J (2005) The metabolic syndrome – a new worldwide definition. Lancet 366: 1059–1062

    Article  PubMed  Google Scholar 

  72. Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689

    Article  PubMed  CAS  Google Scholar 

  73. Iglseder B, Cip P, Malaimare L et al. (2005) The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke 36: 1212–1217

    Article  PubMed  Google Scholar 

  74. Kernan WN, Inzucchi SE, Viscoli CM et al. (2002) Insulin resistance and risk for stroke. Neurology 59: 809–815

    PubMed  CAS  Google Scholar 

  75. Patel PN, Pathak R (2007) Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 64: 481–489

    Article  PubMed  CAS  Google Scholar 

  76. Tanne D, Haim M, Goldbourt U et al. (2003) Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 34: 632–636

    Article  PubMed  Google Scholar 

  77. Giles WH, Croft JB, Greenlund KJ et al. (1998) Total homocyst(e)ine concentration and the likelihood of nonfatal stroke – results from the Third National Health and Nutrition Examination Survey, 1988–1994. Stroke 29: 2473–2477

    PubMed  CAS  Google Scholar 

  78. Toole JF, Malinow MR, Chambless LE (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291: 565–575

    Article  PubMed  CAS  Google Scholar 

  79. Bonaa KH, Njolstad I, Ueland PM et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578–1588

    Article  PubMed  CAS  Google Scholar 

  80. Lonn E, Yusuf S, Arnold MJ et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567–1577

    Article  PubMed  CAS  Google Scholar 

  81. North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325: 445–453

    Article  Google Scholar 

  82. European Carotid Surgery Trialists‘ Collaborative Group (1991) MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 337: 1235–1243

    Article  Google Scholar 

  83. MRC European Carotid Surgery Trial (ECST) (1998) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351: 1379–1387

    Article  Google Scholar 

  84. Mayberg MR, Wilson SE, Yatsu F et al. (1991) Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 266: 3289–3294

    Article  PubMed  CAS  Google Scholar 

  85. Rothwell PM, Eliasziw M, Fox AJ et al. for the Carotid Endarterectomy Trialists‘ Collaboration (2003) Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361: 107–116

    Article  PubMed  CAS  Google Scholar 

  86. Rothwell PM, Eliasziw W, Gutnikov SA et al. for the Carotid Endarterectomy Trialists‘ Collaboration (2004) Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363: 915–924

    Article  PubMed  CAS  Google Scholar 

  87. Nicolaides AN, Shifrin EG, Bradbury A et al. (1996) Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? J Endovasc Surg 3: 158–165

    Article  PubMed  CAS  Google Scholar 

  88. De Bray JM, Glatt B (1995) Quantification of atheromatous stenosis in the extracranial internal carotid artery. Cerebrovasc Dis 5: 414–426

    Article  Google Scholar 

  89. Rantner B, Pavelka M, Posch L et al. (2005) Carotid endarterectomy after ischemic stroke – is there a justification for delayed surgery? Eur J Vasc Endovasc Surg 30: 36–40

    Article  PubMed  CAS  Google Scholar 

  90. Lovett JK, Coull AJ, Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62: 569–573

    PubMed  CAS  Google Scholar 

  91. Blaser T, Hofmann K, Buerger T et al. (2002) Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. Stroke 33: 1057–1062

    Article  PubMed  Google Scholar 

  92. Gasecki AP, Eliasziw M, Ferguson GG et al. (1995) Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. J Neurosurg 83: 778–782

    Article  PubMed  CAS  Google Scholar 

  93. The SPACE Collaborative Group (2006) 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368: 1239–1247

    Article  Google Scholar 

  94. Kern R, Ringleb PA, Hacke W et al. (2007) Stenting for carotid artery stenosis. Nat Clin Pract Neurol 3: 212–220

    Article  PubMed  Google Scholar 

  95. Jean-Louis Mas JL, Chatellier G, Beyssen B et al. (2006) Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355: 1660–1671

    Article  Google Scholar 

  96. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (1995) Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273: 1421–1428

    Article  Google Scholar 

  97. Halliday A, Mansfield A, Marro J et al.; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group (2004) Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363: 1491–1502

    Article  PubMed  CAS  Google Scholar 

  98. Chaturvedi S, Bruno A, Feasby T et al. (2005) Carotid endarterectomy – an evidence-based review. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 65: 794–801

    Article  PubMed  CAS  Google Scholar 

  99. Overell JR, Bone I, Lees KR (2000) Interatrial septal abnormalities and stroke: a metaanalysis of case control studies. Neurology 55: 1172–1179

    PubMed  CAS  Google Scholar 

  100. Meissner I et al. (2006) Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 47: 440–445

    Article  PubMed  Google Scholar 

  101. Agmon Y, Khandheria BK, Meissner I et al. (1999) Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 99: 1942–1924

    PubMed  CAS  Google Scholar 

  102. Mas JL, Arquizan C, Lamy C et al. (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345: 1740–1746

    Article  PubMed  CAS  Google Scholar 

  103. Santamarina E, Gonzalez-Alujas MT, Munoz V et al. (2006) Stroke patients with cardiac atrial septal abnormalities: differential infarct patterns on DWI. J Neuroimaging 16: 334–340

    Article  PubMed  Google Scholar 

  104. Homma S, Sacco RL, DiTullio MR et al. (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation 105: 2625–2631

    Article  PubMed  Google Scholar 

  105. Messe S, Siverman I, Kizer J et al. (2004) Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62: 1042–1050

    PubMed  CAS  Google Scholar 

  106. The Internet Stroke Center Website. Stroke trials directory. Trial PC: patent foramen ovale and cryptogenic embolism. http://www.strokecenter.org/trials/ TrialDetail.aspx? tid=522

  107. Khairy P, O’Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systemic review. Ann Intern Med 139: 753–760

    PubMed  Google Scholar 

  108. Diener HC, Allenberg J-R, Bode C et al. (2005) Leitlinie Primär- und Sekundärprävention der zerebralen Ischämie. Herausgegeben von der Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfall-Gesellschaft (DSG). Thieme, Stuttgart

  109. Stroke Prevention and Educational Awareness Diffusion (SPREAD) (2003) Italian guidelines for stroke prevention and management: syntheses and recommendations. SPREAD, Milan, p 38

  110. U.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH) (2000) CardioSEAL® septal occlusion system transcatheter cardiac occlusion device. Summary of safety and probable benefit. Humanitarian Device Exemption (HDE) No. H990011. FDA, Rockville/MD. http://www.fda.gov/cdrh/pdf/h990011b.pdf. May 17, 2004

  111. TACET – The Austrian paradoxical Cerebral Embolism Trial. http: //www.meduni- graz.at/neurologie/TACET/Home.htm

  112. Erkinjuntti T (1999) Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 12: 35–48

    Article  Google Scholar 

  113. Romàn GC, Erkinjuntti T, Wallin A et al. (2002) Subcortical ischaemic vascular dementia. Lancet Neurol 1: 426–436

    Article  PubMed  Google Scholar 

  114. Zekry D, Hauw JJ, Gold G (2002) Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 50: 1431–1438

    Article  PubMed  Google Scholar 

  115. Forette F, Seux ML, Staessen JA et al. (2002) The prevention of dementia with treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162: 2046–2052

    Article  PubMed  Google Scholar 

  116. Black S, Romàn GC, Geldmacher DS et al.; Donepezil 307 Vascular Dementia Study Group (2003) Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: 2323–2332

    Article  PubMed  CAS  Google Scholar 

  117. Wilkinson D, Doody R, Helme R et al.; Donepezil 308 Study Group (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61: 479–486

    PubMed  CAS  Google Scholar 

  118. Erkinjuntti T, Kurz A, Gauthier S et al. (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283–1290

    Article  PubMed  Google Scholar 

  119. Moretti R, Torre P, Antonello RM et al. (2002) Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 203: 141–146

    Article  PubMed  Google Scholar 

  120. Orgogozo J-M, Rigaud A-S, Stöffler A et al. (2002) Efficacy and safety of menantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834–1839

    Article  PubMed  CAS  Google Scholar 

  121. Wilcock G, Mörbius HJ, Stöffler A on behalf of the MMM 500 group (2002) A double-blind, placebo controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 17: 297–305

    Article  PubMed  CAS  Google Scholar 

  122. Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population. A systematic review. Stroke 34: 2060–2066

    Article  PubMed  CAS  Google Scholar 

  123. Ferro JM (2006) Update on intracerebral haemorrhage. J Neurol 253: 985–999

    Article  PubMed  Google Scholar 

  124. Roob G, Lechner A, Schmidt R et al. (2000) Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke 31: 2665–2669

    PubMed  CAS  Google Scholar 

  125. Jeong SW, Jung KH, Chu K et al. (2004) Clinical and radiologic differences between primary intracerebral hemorrhage with and without microbleeds on gradient-echo magnetic resonance images. Arch Neurol 61: 905–906

    Article  PubMed  Google Scholar 

  126. Davis SM, Broderick J, Hennerici M et al. (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66: 1175–1181

    Article  PubMed  CAS  Google Scholar 

  127. Willmot M, Leonardi-Bee J, Bath PM (2004) High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 43: 18–24

    Article  PubMed  CAS  Google Scholar 

  128. Rochs A, Michelet P, Jullien AC et al. (2004) Longterm outcome in intensive care unit survivors after mechanical ventilation for intracerebral hemorrhage. Crit Care Med 31: 2651–2656

    Article  Google Scholar 

  129. Mayer SA, Brun NC, Begtrup K et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352: 777–785

    Article  PubMed  CAS  Google Scholar 

  130. Mendelow AD, Gregson BA, Fernandes HM et al. STICH Investigators (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet 365: 387–397

    PubMed  Google Scholar 

  131. Engelhard HH, Andrews CO, Slavin KV, Charbel FT (2003) Current management of intraventricular hemorrhage. Surg Neurol 60: 15–22

    Article  PubMed  Google Scholar 

  132. Naff NJ, Carhuapoma JR, Williams MA et al. (2000) Treatment of intraventricular hemorrhage with urokinase. Effect on 30-day survival. Stroke 31: 841–847

    PubMed  CAS  Google Scholar 

  133. Naff NJ, Hanley DF, Keyl PM et al. (2004) Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 54: 577–584

    Article  PubMed  Google Scholar 

  134. Maramattom BV, Weigand S, Reinalda M et al. (2006) Pulmonary complications after intracerebral hemorrhage. Neurocrit Care 5: 115–119

    Article  PubMed  Google Scholar 

  135. Delgado P, Alvarez Sabin J, Santamarina E et al. (2006) Plasma S100 B level after acute spontaneous intracerebral hemorrhage. Stroke 37: 2837–2839

    Article  PubMed  CAS  Google Scholar 

  136. Hornig CR, Rust DS, Busse O et al. (1994) Space-occupying cerebellar infarction. Clinical course and prognosis. Stroke 25: 372–374

    PubMed  CAS  Google Scholar 

  137. Vahedi K, Hofmeijer J, Juettler E et al. for the DECIMAL, DESTINY, and HAMLET investigators (2007) Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6: 215–222

    Article  PubMed  Google Scholar 

  138. Uhl E, Kreth FW, Elias B et al. (2004) Outcome and prognostic factors of hemicraniectomy for space occupying cerebral infarction. J Neurol Neurosurg Psychiatry 75: 270–274

    PubMed  CAS  Google Scholar 

  139. Aichner FT (2003) Diagnostik des Schlaganfalls – ein Update. Wien Med Wochenschr 153: 14–20

    Article  PubMed  Google Scholar 

  140. Brainin M, Olsen TS, Chamorro A et al. for the EUSI Executive Committee (2004) EUSI Writing Committee Organization of stroke care: education, referral, emergency management and imaging, stroke units and rehabilitation. European Stroke Initiative. Cerebrovasc Dis (Suppl 2) 17: 1–14

    Article  Google Scholar 

  141. Diener HC et al. (2005) Ischämischer Schlaganfall: Akuttherapie. Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S 176–191

  142. Latchaw RE, Yonas H, Hunter GJ et al. Council on Cardiovascular Radiology of the American Heart Association (2003) AHA guidelines and recommendations for perfusion imaging in cerebral ischemia. A scientific statement for healthcare professionals by the Writing Group on Perfusion Imaging. Stroke 34: 1084–1104

    Article  PubMed  Google Scholar 

  143. Masdeu JC, Irimia P, Asenbaum S et al. for the EFNS (2006) EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force. Eur J Neurol 13: 1271–1283

    Article  PubMed  CAS  Google Scholar 

  144. Brainin M, Barnes M, Baron JC et al.; Guideline Standards Subcommittee of the EFNS Scientific Committee (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur J Neurol 11: 577–581

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Univ.-Klinik für Neurologie, Medizinische Universität Innsbruck, Innsbruck, Österreich

    J. Willeit, S. Kiechl & E. Schmutzhard

  2. Neurologische Abteilung, Landesnervenklinik Wagner-Jauregg, Linz, Österreich

    F. Aichner & H.P. Haring

  3. Abteilung für Neurologie, Krankenhaus Kufstein, Kufstein, Österreich

    K. Berek

  4. Neurologisches Zentrum Rothschildstiftung Maria-Theresien-Schlössel, Wien, Österreich

    H. Binder

  5. Klinische Neurowissenschaften, Donau-Universität Krems, Krems, Österreich

    M. Brainin

  6. Abteilung Neurologie, Landesklinikum Donauregion Tulln, Tulln, Österreich

    M. Brainin

  7. Univ.-Klinik für Neurologie, Medizinische Universität Graz, Graz, Österreich

    F. Fazekas, S. Horner, K. Niederkorn & R. Schmidt

  8. Abteilung für Gefäßchirurgie, Univ.-Klinik für Chirurgie, Medizinische Universität Innsbruck, Anichstraße 35, A-6020, Innsbruck, Österreich

    G. Fraedrich

  9. Univ.-Klinik für Geriatrie, Christian-Doppler-Klinik , Salzburg, Österreich

    B. Iglseder

  10. Abteilung für Neurologie, Landeskrankenhaus Villach, Villach, Österreich

    P. Kapeller

  11. Neurologische Abteilung, Krankenhaus der Barmherzigen Brüder, Wien, Österreich

    W. Lang & E. Minar

  12. Abteilung für Neurologie, Landeskrankenhaus Klagenfurt, Klagenfurt, Österreich

    G. Noisternig

  13. Abteilung für Kardiologie, Wilhelminenspital, Wien, Österreich

    M. Schillinger

  14. Radiologische Abteilung, Krankenhaus der Barmherzigen Schwestern, Linz, Österreich

    P. Waldenberger

  15. Neurologische Abteilung, Landesnervenklinik Sigmund Freud, Graz, Österreich

    H.W. Wege

Authors
  1. J. Willeit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kiechl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Aichner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Berek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Binder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Brainin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Fazekas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Fraedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H.P. Haring
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Horner
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Iglseder
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P. Kapeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. W. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E. Minar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. K. Niederkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. G. Noisternig
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M. Schillinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. R. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. E. Schmutzhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. P. Waldenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. H.W. Wege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Fraedrich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willeit, J., Kiechl, S., Aichner, F. et al. Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13, 115–125 (2008). https://doi.org/10.1007/s00772-007-0568-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-007-0568-2

Search

Navigation